Skip to main content
ATHE logo

ATHE

Alterity Therapeutics Ltd
$5.43 +0.05 (+0.93%) At close · Jul 10
Market Cap
$98.42M
Shares
18,125,694

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.43 Open$5.47 Day$5.38–5.55 52W$2.66–7.00 Avg vol 30d78K Short int39K · 0.2% float · 1.2d Short vol63% Last earningsDec 31, 2020 DataJan 2020–Jul 2026
Up next
FQ1-27 quarter ends
~Sep 30, 2026 Est
Equibles Rating blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.55
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +38%
above
Price vs 50-day avg +18%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 64%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +31%
trailing
6-month return +64%
trailing
YTD return +76%
this year
Relative strength +55%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
2 of 15 funds reported for Jun 30 · net +453 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.22% of float · ▼ -27.8% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −55%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+38% Bullish
Price vs 50-day avg
+18% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
64% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
2 of 15 funds reported for Jun 30 · net +453 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.22% of float · ▼ -27.8% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3 Now $5 · 64% 52-wk high $7
vs 200-day avg +38% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATHE
Alterity Therapeutics Ltd
this stock
$98.42M +76.3% 0.2%
ONC
BeOne Medicines Ltd.
$431.70B -1.7% +22179.2% 878.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.19B +9.5% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$69.63B -13.8% +20.8% 16.2 3.3%
ARGX
Argenx SE
$54.85B +4.4% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
1.8%
Reported
2 of 15
Top holder
Twin Lakes Capital Manage…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
39.0K
Days to cover
1.2d
Change
-15.0K sh
View
Short Volume
Short vol %
63%
As of
Jul 10, 2026
Short Total
View
Fails to Deliver
FTD shares
102
Value
$438
As of
Jun 10, 2026
View
Off-Exchange
Off-exchange %
32.2%
Week of
May 4, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 9, 2026
This year
45
View
Earnings & Events
Earnings Calls
Last call
Dec 31, 2020
View

Performance

5D 20D 120D MTD YTD
ATHE +1.3% +30.8% +64.1% +1.1% +76.3%
SPY +1.4% +4.1% +9.1% +1.1% +10.7%
vs SPY -0.1% +26.8% +55.0% +0.0% +65.6%
Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 2 filings 2 filers Visit website Investor relations